O66 CONCORDANCE BETWEEN THE PULSE WAVE VELOCITY ESTIMATED WITH TOTAL ARTERIAL COMPLIANCE AND CAROTID-FEMORAL PULSE WAVE VELOCITY MEASUREMENTS

Background and Objective: Carotid-femoral pulse wave velocity (cfPWV), considered a reference measure of aortic stiffness, plays a role in cardiovascular risk stratification. However, its application in clinical settings has been limited due to the need for additional equipment and trained personnel. Recently, our group developed a non-invasive method to estimate pulse wave velocity (PWV) based on total arterial compliance (Ct). Yet, the validity of this method remains uncertain. The objective was to evaluate the concordance between PWV estimated using Ct and cfPWV. Methods: A cross-sectional study was conducted involving 56 adult patients who visited an outpatient cardiology center due to suspected hypertension. All participants underwent 24-hour ambulatory blood pressure monitoring (24-h ABPM). PWV was measured in all patients using two methods: i) the applanation tonometry technique, utilizing the SphygmoCor device (AtCor Medical, West Ryde, NSW, Australia); and ii) a novel method based on Ct derived from blood pressure and heart rate data obtained from 24-h ABPM, without the need for a pulse wave. This method utilized the relationship between Ct and PWV proposed by Vardoulis et al., derived from the Bramwell-Hill theory and experimental research, where PWV=√(36.7/Ct). Results: Among the participants, 58.9% were men, with an average age of 50.4±16.5 years and a body mass index of 28.0±4.3 kg/m 2 . The agreement of the PWV between the new method based on Ct and cfPWV was found to be very good (ICC 0.675; 95% CI 0.498 to 0.797), with a mean difference of 0.388±1.262 m/s (95% CI 0.050 to 0.726). Bland-Altman plots revealed that the differences between the methods were randomly distributed along the mean difference line (Figure). Conclusions: The ability to estimate PWV in humans using a new method based on Ct represents a significant advancement. This finding has the potential to streamline the implementation of PWV measurement as a risk marker in clinical practice.